Cellexus partner with Verder to upgrade bioreactor systems

Dundee-based life sciences firm, Cellexus, have partnered with Castleford-based Verder Liquids to provide pumps to be used for the acid / base pump included as standard with their CellMaker Plus and Low Flow bioreactor systems.

The CellMaker bioreactor system is used by scientists across the globe to produce cells in their laboratories for use in experiments to develop new medicines and vaccines.

The acid / base pump is used with the CellMaker Plus and Low Flow bioreactor systems to automatically manage the pH levels within the single-use bioreactor bags.

The pumps supplied by Verder speed up and simplify tube loading.

The Plus and Low Flow bioreactor system is used for more complex cell culture and fermentation, where pH and Dissolved Oxygen are required. These include cutting edge science such as stem cells and lab meat, as well as mammalian cells used in cancer research.

Cells are grown inside single-use bags, which are connected to the enclosure, and monitored through a controller. Single-use technology allows researchers to swap between experiments quickly without having to clean the device between batches, saving time and speeding up their work.

The device also uses “airlift” technology, where bubbles gases up through the bags to stir the ingredients for creating cells, rather than using mechanical stirred bioreactors that then need to be cleaned with expensive chemicals.

The airlift technology allows researchers to produce higher quantities of cells or bacteriophages from each batch, improving their yield and efficiency.

Gavin Hands, CEO at Cellexus, said: “We are continually impressed by Verder, and are happy to have found not only a solution to our problem, but a key partnership for our business. We are continually improving the CellMaker bioreactor system, and these new pumps help scientists get their bioreactor up and running quicker than ever.”

More news and updates

University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations

University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.

CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine

CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

Coulter Partners top hires for VC & PE portfolio companies Q1-2024

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

 

More within